Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Tackling gaps in developing life-changing treatments for dementia.

Mauricio R, Benn C, Davis J, Dawson G, Dawson LA, Evans A, Fox N, Gallacher J, Hutton M, Isaac J, Jones DNC, Jones L, Lalli G, Libri V, Lovestone S, Moody C, Noble W, Perry H, Pickett J, Reynolds D, Ritchie C, Rohrer JD, Routledge C, Rowe J, Snyder H, Spires-Jones T, Swartz J, Truyen L, Whiting P; Therapeutics for Dementia Consortium.

Alzheimers Dement (N Y). 2019 Jun 24;5:241-253. doi: 10.1016/j.trci.2019.05.001. eCollection 2019. Review.

2.

New terminology for a common TDP-43 proteinopathy.

Kurucu H, Spires-Jones T, Smith C.

Lancet Neurol. 2019 Aug;18(8):714-715. doi: 10.1016/S1474-4422(19)30223-6. Epub 2019 Jun 12. No abstract available.

PMID:
31202672
3.

Nanoscale structure of amyloid-β plaques in Alzheimer's disease.

Querol-Vilaseca M, Colom-Cadena M, Pegueroles J, Nuñez-Llaves R, Luque-Cabecerans J, Muñoz-Llahuna L, Andilla J, Belbin O, Spires-Jones TL, Gelpi E, Clarimon J, Loza-Alvarez P, Fortea J, Lleó A.

Sci Rep. 2019 Mar 26;9(1):5181. doi: 10.1038/s41598-019-41443-3.

4.

Sleep well to slow Alzheimer's progression?

Noble W, Spires-Jones TL.

Science. 2019 Feb 22;363(6429):813-814. doi: 10.1126/science.aaw5583. No abstract available.

PMID:
30792288
5.

Opposing Roles of apolipoprotein E in aging and neurodegeneration.

Hudry E, Klickstein J, Cannavo C, Jackson R, Muzikansky A, Gandhi S, Urick D, Sargent T, Wrobleski L, Roe AD, Hou SS, Kuchibhotla KV, Betensky RA, Spires-Jones T, Hyman BT.

Life Sci Alliance. 2019 Feb 13;2(1). pii: e201900325. doi: 10.26508/lsa.201900325. Print 2019 Feb.

6.

Beyond the neuron-cellular interactions early in Alzheimer disease pathogenesis.

Henstridge CM, Hyman BT, Spires-Jones TL.

Nat Rev Neurosci. 2019 Feb;20(2):94-108. doi: 10.1038/s41583-018-0113-1. Review.

7.

Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid.

Lleó A, Núñez-Llaves R, Alcolea D, Chiva C, Balateu-Paños D, Colom-Cadena M, Gomez-Giro G, Muñoz L, Querol-Vilaseca M, Pegueroles J, Rami L, Lladó A, Molinuevo JL, Tainta M, Clarimón J, Spires-Jones T, Blesa R, Fortea J, Martínez-Lage P, Sánchez-Valle R, Sabidó E, Bayés À, Belbin O.

Mol Cell Proteomics. 2019 Mar;18(3):546-560. doi: 10.1074/mcp.RA118.001290. Epub 2019 Jan 3.

PMID:
30606734
8.

Trajectories of inflammatory biomarkers over the eighth decade and their associations with immune cell profiles and epigenetic ageing.

Stevenson AJ, McCartney DL, Harris SE, Taylor AM, Redmond P, Starr JM, Zhang Q, McRae AF, Wray NR, Spires-Jones TL, McColl BW, McIntosh AM, Deary IJ, Marioni RE.

Clin Epigenetics. 2018 Dec 20;10(1):159. doi: 10.1186/s13148-018-0585-x.

9.

Complementing Tau: New Data Show that the Complement System Is Involved in Degeneration in Tauopathies.

Davies C, Spires-Jones TL.

Neuron. 2018 Dec 19;100(6):1267-1269. doi: 10.1016/j.neuron.2018.12.003.

PMID:
30571935
10.

Invited Review: APOE at the interface of inflammation, neurodegeneration and pathological protein spread in Alzheimer's disease.

Tzioras M, Davies C, Newman A, Jackson R, Spires-Jones T.

Neuropathol Appl Neurobiol. 2019 Jun;45(4):327-346. doi: 10.1111/nan.12529. Epub 2018 Nov 28. Review.

11.

Region-specific depletion of synaptic mitochondria in the brains of patients with Alzheimer's disease.

Pickett EK, Rose J, McCrory C, McKenzie CA, King D, Smith C, Gillingwater TH, Henstridge CM, Spires-Jones TL.

Acta Neuropathol. 2018 Nov;136(5):747-757. doi: 10.1007/s00401-018-1903-2. Epub 2018 Sep 6.

12.

A brain boost to fight Alzheimer's disease.

Spires-Jones TL, Ritchie CW.

Science. 2018 Sep 7;361(6406):975-976. doi: 10.1126/science.aau8060. No abstract available.

PMID:
30190391
13.

Modeling Alzheimer's disease brains in vitro.

Henstridge CM, Spires-Jones TL.

Nat Neurosci. 2018 Jul;21(7):899-900. doi: 10.1038/s41593-018-0177-2. No abstract available.

PMID:
29950667
14.

sAPPβ and sAPPα increase structural complexity and E/I input ratio in primary hippocampal neurons and alter Ca2+ homeostasis and CREB1-signaling.

Hesse R, von Einem B, Wagner F, Bott P, Schwanzar D, Jackson RJ, Föhr KJ, Lausser L, Kroker KS, Proepper C, Walther P, Kestler HA, Spires-Jones TL, Boeckers T, Rosenbrock H, von Arnim CAF.

Exp Neurol. 2018 Jun;304:1-13. doi: 10.1016/j.expneurol.2018.02.010. Epub 2018 Feb 18.

PMID:
29466703
15.

Synaptogyrin-3 Mediates Presynaptic Dysfunction Induced by Tau.

McInnes J, Wierda K, Snellinx A, Bounti L, Wang YC, Stancu IC, Apóstolo N, Gevaert K, Dewachter I, Spires-Jones TL, De Strooper B, De Wit J, Zhou L, Verstreken P.

Neuron. 2018 Feb 21;97(4):823-835.e8. doi: 10.1016/j.neuron.2018.01.022. Epub 2018 Feb 1.

16.

Synapse loss in the prefrontal cortex is associated with cognitive decline in amyotrophic lateral sclerosis.

Henstridge CM, Sideris DI, Carroll E, Rotariu S, Salomonsson S, Tzioras M, McKenzie CA, Smith C, von Arnim CAF, Ludolph AC, Lulé D, Leighton D, Warner J, Cleary E, Newton J, Swingler R, Chandran S, Gillingwater TH, Abrahams S, Spires-Jones TL.

Acta Neuropathol. 2018 Feb;135(2):213-226. doi: 10.1007/s00401-017-1797-4. Epub 2017 Dec 22.

17.

Antidiabetic Polypill Improves Central Pathology and Cognitive Impairment in a Mixed Model of Alzheimer's Disease and Type 2 Diabetes.

Infante-Garcia C, Ramos-Rodriguez JJ, Hierro-Bujalance C, Ortegon E, Pickett E, Jackson R, Hernandez-Pacho F, Spires-Jones T, Garcia-Alloza M.

Mol Neurobiol. 2018 Jul;55(7):6130-6144. doi: 10.1007/s12035-017-0825-7. Epub 2017 Dec 9.

PMID:
29224179
18.

Synaptic phosphorylated α-synuclein in dementia with Lewy bodies.

Colom-Cadena M, Pegueroles J, Herrmann AG, Henstridge CM, Muñoz L, Querol-Vilaseca M, Martín-Paniello CS, Luque-Cabecerans J, Clarimon J, Belbin O, Núñez-Llaves R, Blesa R, Smith C, McKenzie CA, Frosch MP, Roe A, Fortea J, Andilla J, Loza-Alvarez P, Gelpi E, Hyman BT, Spires-Jones TL, Lleó A.

Brain. 2017 Dec 1;140(12):3204-3214. doi: 10.1093/brain/awx275.

19.

Conditional Deletion of PDK1 in the Forebrain Causes Neuron Loss and Increased Apoptosis during Cortical Development.

Xu C, Yu L, Hou J, Jackson RJ, Wang H, Huang C, Liu T, Wang Q, Zou X, Morris RG, Spires-Jones TL, Yang Z, Yin Z, Xu Y, Chen G.

Front Cell Neurosci. 2017 Oct 20;11:330. doi: 10.3389/fncel.2017.00330. eCollection 2017.

20.

Human Brain-Derived Aβ Oligomers Bind to Synapses and Disrupt Synaptic Activity in a Manner That Requires APP.

Wang Z, Jackson RJ, Hong W, Taylor WM, Corbett GT, Moreno A, Liu W, Li S, Frosch MP, Slutsky I, Young-Pearse TL, Spires-Jones TL, Walsh DM.

J Neurosci. 2017 Dec 6;37(49):11947-11966. doi: 10.1523/JNEUROSCI.2009-17.2017. Epub 2017 Nov 3.

21.

TDP-43 Depletion in Microglia Promotes Amyloid Clearance but Also Induces Synapse Loss.

Paolicelli RC, Jawaid A, Henstridge CM, Valeri A, Merlini M, Robinson JL, Lee EB, Rose J, Appel S, Lee VM, Trojanowski JQ, Spires-Jones T, Schulz PE, Rajendran L.

Neuron. 2017 Jul 19;95(2):297-308.e6. doi: 10.1016/j.neuron.2017.05.037. Epub 2017 Jun 29.

22.

Tau association with synaptic vesicles causes presynaptic dysfunction.

Zhou L, McInnes J, Wierda K, Holt M, Herrmann AG, Jackson RJ, Wang YC, Swerts J, Beyens J, Miskiewicz K, Vilain S, Dewachter I, Moechars D, De Strooper B, Spires-Jones TL, De Wit J, Verstreken P.

Nat Commun. 2017 May 11;8:15295. doi: 10.1038/ncomms15295.

23.

Interactions of pathological proteins in neurodegenerative diseases.

Spires-Jones TL, Attems J, Thal DR.

Acta Neuropathol. 2017 Aug;134(2):187-205. doi: 10.1007/s00401-017-1709-7. Epub 2017 Apr 11. Review.

24.

Spread of tau down neural circuits precedes synapse and neuronal loss in the rTgTauEC mouse model of early Alzheimer's disease.

Pickett EK, Henstridge CM, Allison E, Pitstick R, Pooler A, Wegmann S, Carlson G, Hyman BT, Spires-Jones TL.

Synapse. 2017 Jun;71(6). doi: 10.1002/syn.21965. Epub 2017 Mar 6.

25.

Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease.

Jackson RJ, Rudinskiy N, Herrmann AG, Croft S, Kim JM, Petrova V, Ramos-Rodriguez JJ, Pitstick R, Wegmann S, Garcia-Alloza M, Carlson GA, Hyman BT, Spires-Jones TL.

Eur J Neurosci. 2016 Dec;44(12):3056-3066. doi: 10.1111/ejn.13442. Epub 2016 Nov 12.

26.

Non-Fibrillar Oligomeric Amyloid-β within Synapses.

Pickett EK, Koffie RM, Wegmann S, Henstridge CM, Herrmann AG, Colom-Cadena M, Lleo A, Kay KR, Vaught M, Soberman R, Walsh DM, Hyman BT, Spires-Jones TL.

J Alzheimers Dis. 2016 May 30;53(3):787-800. doi: 10.3233/JAD-160007.

PMID:
27258414
27.

Progressive Neuronal Pathology and Synaptic Loss Induced by Prediabetes and Type 2 Diabetes in a Mouse Model of Alzheimer's Disease.

Ramos-Rodriguez JJ, Spires-Jones T, Pooler AM, Lechuga-Sancho AM, Bacskai BJ, Garcia-Alloza M.

Mol Neurobiol. 2017 Jul;54(5):3428-3438. doi: 10.1007/s12035-016-9921-3. Epub 2016 May 14.

PMID:
27177549
28.

Amyloid-beta oligomerization is associated with the generation of a typical peptide fragment fingerprint.

Rudinskiy N, Fuerer C, Demurtas D, Zamorano S, De Piano C, Herrmann AG, Spires-Jones TL, Oeckl P, Otto M, Frosch MP, Moniatte M, Hyman BT, Schmid AW.

Alzheimers Dement. 2016 Sep;12(9):996-1013. doi: 10.1016/j.jalz.2016.03.011. Epub 2016 Apr 26.

PMID:
27130892
29.

Synaptic pathology: A shared mechanism in neurological disease.

Henstridge CM, Pickett E, Spires-Jones TL.

Ageing Res Rev. 2016 Jul;28:72-84. doi: 10.1016/j.arr.2016.04.005. Epub 2016 Apr 20. Review.

30.

Opening up: open access publishing, data sharing, and how they can influence your neuroscience career.

Spires-Jones TL, Poirazi P, Grubb MS.

Eur J Neurosci. 2016 Jun;43(11):1413-9. doi: 10.1111/ejn.13234. Epub 2016 Apr 6. No abstract available.

PMID:
26950407
31.

Erratum to: Post-mortem brain analyses of the Lothian Birth Cohort 1936: extending lifetime cognitive and brain phenotyping to the level of the synapse.

Henstridge CM, Jackson RJ, Kim JM, Herrmann AG, Wright AK, Harris SE, Bastin ME, Starr JM, Wardlaw J, Gillingwater TH, Smith C, McKenzie CA, Cox SR, Deary IJ, Spires-Jones TL.

Acta Neuropathol Commun. 2015 Dec 9;3(1):83. doi: 10.1186/s40478-015-0244-9.

32.

Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity.

Wegmann S, Maury EA, Kirk MJ, Saqran L, Roe A, DeVos SL, Nicholls S, Fan Z, Takeda S, Cagsal-Getkin O, William CM, Spires-Jones TL, Pitstick R, Carlson GA, Pooler AM, Hyman BT.

EMBO J. 2015 Dec 14;34(24):3028-41. doi: 10.15252/embj.201592748. Epub 2015 Nov 4.

33.

You are not alone: selecting your group members and leading an outstanding research team.

Hanganu-Opatz IL, Mameli M, Káradóttir RT, Spires-Jones TL.

Eur J Neurosci. 2015 Dec;42(12):3012-7. doi: 10.1111/ejn.13109. Epub 2015 Nov 27. No abstract available.

PMID:
26494052
34.

Post-mortem brain analyses of the Lothian Birth Cohort 1936: extending lifetime cognitive and brain phenotyping to the level of the synapse.

Henstridge CM, Jackson RJ, Kim JM, Herrmann AG, Wright AK, Harris SE, Bastin ME, Starr JM, Wardlaw J, Gillingwater TH, Smith C, McKenzie CA, Cox SR, Deary IJ, Spires-Jones TL.

Acta Neuropathol Commun. 2015 Sep 4;3:53. doi: 10.1186/s40478-015-0232-0. Erratum in: Acta Neuropathol Commun. 2015;3(1):83.

35.

Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer's disease.

Pooler AM, Polydoro M, Maury EA, Nicholls SB, Reddy SM, Wegmann S, William C, Saqran L, Cagsal-Getkin O, Pitstick R, Beier DR, Carlson GA, Spires-Jones TL, Hyman BT.

Acta Neuropathol Commun. 2015 Mar 24;3:14. doi: 10.1186/s40478-015-0199-x.

36.

Pathological tau disrupts ongoing network activity.

Menkes-Caspi N, Yamin HG, Kellner V, Spires-Jones TL, Cohen D, Stern EA.

Neuron. 2015 Mar 4;85(5):959-66. doi: 10.1016/j.neuron.2015.01.025. Epub 2015 Feb 19.

37.

Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity.

Izzo NJ, Xu J, Zeng C, Kirk MJ, Mozzoni K, Silky C, Rehak C, Yurko R, Look G, Rishton G, Safferstein H, Cruchaga C, Goate A, Cahill MA, Arancio O, Mach RH, Craven R, Head E, LeVine H 3rd, Spires-Jones TL, Catalano SM.

PLoS One. 2014 Nov 12;9(11):e111899. doi: 10.1371/journal.pone.0111899. eCollection 2014.

38.

The calcium-binding protein EFhd2 modulates synapse formation in vitro and is linked to human dementia.

Borger E, Herrmann A, Mann DA, Spires-Jones T, Gunn-Moore F.

J Neuropathol Exp Neurol. 2014 Dec;73(12):1166-82. doi: 10.1097/NEN.0000000000000138.

39.

Carboxy terminus heat shock protein 70 interacting protein reduces tau-associated degenerative changes.

Saidi LJ, Polydoro M, Kay KR, Sanchez L, Mandelkow EM, Hyman BT, Spires-Jones TL.

J Alzheimers Dis. 2015;44(3):937-47. doi: 10.3233/JAD-142094.

PMID:
25374103
40.

Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimer's disease.

Tai HC, Wang BY, Serrano-Pozo A, Frosch MP, Spires-Jones TL, Hyman BT.

Acta Neuropathol Commun. 2014 Oct 21;2:146. doi: 10.1186/s40478-014-0146-2.

41.

Clearing the way for tau immunotherapy in Alzheimer's disease.

Herrmann A, Spires-Jones T.

J Neurochem. 2015 Jan;132(1):1-4. doi: 10.1111/jnc.12845. Epub 2014 Aug 23. No abstract available.

42.

Synapse density and dendritic complexity are reduced in the prefrontal cortex following seven days of forced abstinence from cocaine self-administration.

Rasakham K, Schmidt HD, Kay K, Huizenga MN, Calcagno N, Pierce RC, Spires-Jones TL, Sadri-Vakili G.

PLoS One. 2014 Jul 29;9(7):e102524. doi: 10.1371/journal.pone.0102524. eCollection 2014.

43.

Tau pathology does not affect experience-driven single-neuron and network-wide Arc/Arg3.1 responses.

Rudinskiy N, Hawkes JM, Wegmann S, Kuchibhotla KV, Muzikansky A, Betensky RA, Spires-Jones TL, Hyman BT.

Acta Neuropathol Commun. 2014 Jun 10;2:63. doi: 10.1186/2051-5960-2-63.

44.

The intersection of amyloid beta and tau at synapses in Alzheimer's disease.

Spires-Jones TL, Hyman BT.

Neuron. 2014 May 21;82(4):756-71. doi: 10.1016/j.neuron.2014.05.004. Review.

45.

Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy.

Spires-Jones TL, Friedman T, Pitstick R, Polydoro M, Roe A, Carlson GA, Hyman BT.

Neurosci Lett. 2014 Mar 6;562:63-8. doi: 10.1016/j.neulet.2014.01.013. Epub 2014 Jan 21.

46.

Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo.

Kuchibhotla KV, Wegmann S, Kopeikina KJ, Hawkes J, Rudinskiy N, Andermann ML, Spires-Jones TL, Bacskai BJ, Hyman BT.

Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):510-4. doi: 10.1073/pnas.1318807111. Epub 2013 Dec 24.

47.

Tau causes synapse loss without disrupting calcium homeostasis in the rTg4510 model of tauopathy.

Kopeikina KJ, Wegmann S, Pitstick R, Carlson GA, Bacskai BJ, Betensky RA, Hyman BT, Spires-Jones TL.

PLoS One. 2013 Nov 20;8(11):e80834. doi: 10.1371/journal.pone.0080834. eCollection 2013.

48.

Soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early Alzheimer's disease model.

Polydoro M, Dzhala VI, Pooler AM, Nicholls SB, McKinney AP, Sanchez L, Pitstick R, Carlson GA, Staley KJ, Spires-Jones TL, Hyman BT.

Acta Neuropathol. 2014 Feb;127(2):257-70. doi: 10.1007/s00401-013-1215-5. Epub 2013 Nov 24.

49.

Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain.

Hudry E, Dashkoff J, Roe AD, Takeda S, Koffie RM, Hashimoto T, Scheel M, Spires-Jones T, Arbel-Ornath M, Betensky R, Davidson BL, Hyman BT.

Sci Transl Med. 2013 Nov 20;5(212):212ra161. doi: 10.1126/scitranslmed.3007000.

50.

Propagation of tau pathology in Alzheimer's disease: identification of novel therapeutic targets.

Pooler AM, Polydoro M, Wegmann S, Nicholls SB, Spires-Jones TL, Hyman BT.

Alzheimers Res Ther. 2013 Oct 23;5(5):49. doi: 10.1186/alzrt214. eCollection 2013. Review.

Supplemental Content

Loading ...
Support Center